P. Peterson

发表

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

R. Ramlau, M. Krzakowski, A. Santoro, 2012, The Lancet. Oncology.

Phase I I, R andomized, D ouble-Blind S tudy o f T wo D ose L evels of A rzoxifene i n P atients W ith L ocally A dvanced o r M etastatic Breast C ancer

C. Hudis, D. Booser, A. Buzdar, 2003 .

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.

S. Novello, P. Zatloukal, N. Iscoe, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328

G. Scagliotti, Keunchil Park, U. Gatzemeier, 2007 .

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

J. Canon, R. Pirker, J. Vansteenkiste, 2005, Investigational New Drugs.

Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer

C. Rudin, M. Edelman, W. John, 2006 .

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial

Yi-long Wu, Yuh-Min Chen, Joo‐Hang Kim, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).

K. Krejcy, M. Krzakowski, J. Kim, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

K. Krejcy, Yi-long Wu, M. Krzakowski, 2009, The Lancet.

Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies.

M. Rizzo, E. Garon, P. Peterson, 2021, Clinical lung cancer.

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).

K. Krejcy, M. Krzakowski, J. Kim, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study

R. Ramlau, A. Santoro, F. Franke, 2008 .

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

G. Scagliotti, Keunchil Park, S. Gans, 2009, European journal of cancer.

6521 POSTER Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)

G. Scagliotti, Keunchil Park, U. Gatzemeier, 2007 .

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

M. Gore, R. Ilaria, R. Penson, 2018, BMC Cancer.

Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.

W. Shen, E. Cohen, A. Hossain, 2012, Oral oncology.

External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer

C. Rolfo, Y. Summers, T. Sugihara, 2022, ESMO open.

A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy

M. Arning, D. Roychowdhury, P. Peterson, 2002, Investigational New Drugs.

Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy.

R. Ramlau, M. Krzakowski, T. Ciuleanu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189

S. Gadgeel, M. Rizzo, J. Gray, 2022, JTO clinical and research reports.

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

Robin L. Jones, W. Tap, R. Ilaria, 2018, Cancer Chemotherapy and Pharmacology.

Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule

D. Roychowdhury, L. Cirera, P. Peterson, 2001, Anti-cancer drugs.

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

M. Rizzo, Yongmei Chen, X. Le, 2022, Cancers.

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

G. Scagliotti, S. Novello, L. Crinò, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

G. Scagliotti, N. Hanna, F. Shepherd, 2009, The oncologist.

Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.

A. Buzdar, S. Krishnamurthy, A. Melemed, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study

Yi-long Wu, M. Krzakowski, T. Ciuleanu, 2008 .

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.

José Miguel Reyes, Jean-Yves Douillard, Michael Lahn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.

G. Scagliotti, C. Gridelli, C. Langer, 2012, Clinical lung cancer.

Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer

W. Shen, W. John, A. Melemed, 2016, Health and Quality of Life Outcomes.

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.

M. Socinski, E. Smit, P. Lorigan, 2012, Lung cancer.

An analysis of efficacy and safety of olaratumab + doxorubicin or doxorubicin alone in patients with uterine leiomyosarcoma: A retrospective assessment of the phase 1b/2 study JGDG

Robin L. Jones, R. Ilaria, B. A. Tine, 2017 .

The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial

G. Scagliotti, C. Gridelli, M. Rinaldi, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations.

Yongmei Chen, M. Leusch, C. Visseren-Grul, 2021, Future oncology.

Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

Robin L. Jones, W. Tap, B. V. Van Tine, 2021, Clinical Cancer Research.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

G. Scagliotti, C. Gridelli, F. de Marinis, 2014, Lung cancer.

Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial

A. Rossi, C. Gridelli, A. Favaretto, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study

E. Van Cutsem, Z. Wainberg, K. Muro, 2023, Journal of gastric cancer.

M. Gore, R. Ilaria, R. Penson, 2018, BMC Cancer.

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis

D. Berry, M. Salzberg, J. Pujol, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial

C. Schumann, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.

C. Hudis, D. Booser, A. Buzdar, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.

Mark R. Green, M. Eaddy, S. Gruschkus, 2013, Lung cancer.

Health and resource burden of a cancer diagnosis on the caregiver: an analysis of administrative claims data

L. Hess, P. Peterson, S. Wong-Jacobson, 2021, BMC Health Services Research.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

G. Scagliotti, N. Hanna, F. Shepherd, 2009, The oncologist.

Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer

F. de Marinis, M. Salzberg, J. Jassem, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189

S. Gadgeel, M. Rizzo, J. Gray, 2022, JTO clinical and research reports.

Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.

J. Aerts, S. Gadgeel, M. Rizzo, 2021, Lung cancer.